Wird geladen...
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). Novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms o...
Gespeichert in:
| Veröffentlicht in: | Clin Pharmacol Ther |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715745/ https://ncbi.nlm.nih.gov/pubmed/26331358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.256 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|